News

ORIX Capital Partners collects $160.3 mln for inaugural fund

New York City-based ORIX Capital Partners, a middle-market private equity firm, has raised $160.3 million for its debut fund, according to an SEC filing. No target was listed on the document.

Eight hauls in $14 mln Series B in Khosla Ventures-led round

New York City-based Eight, a tech company focused on improving how people sleep, has secured $14 million in Series B funding. Khosla Ventures led the round with participation from Y Combinator and Yunqi Partners.

Prime Venture Partners wraps up third fund at $60 mln

India-based Prime Venture Partners, an early-stage venture firm, has closed its third fund at $60 million. The fund will invest in a number of sectors that include healthcare, education, logistics and fintech/financial services.

Phyto Partners launches second cannabis venture fund

Boca Raton, Florida-based Phyto Partners has launched its second cannabis venture fund Phyto II. The $100 million fund will back companies that provide business critical services and solutions to the growing cannabis sector.

Metactive Medical fetches $1.2 mln Series A

Metactive Medical Inc, a developer of products for the treatment of neurovascular, peripheral vascular and structural heart diseases, has raised $1.2 million in Series A financing. The investors included Mid-America Angels and Serra Ventures.

Allegion unveils new venture fund

Dublin-based Allegion plc, a global security products and solutions provider, has launched Allegion Ventures, a $50 million corporate venture fund. Allegion Ventures will back early-stage companies. Allegion has teamed up with Touchdown Ventures to help in managing the fund.

Prevail Therapeutics lands $75 mln Series A

New York City-based Prevail Therapeutics Inc, a developer of gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, has secured $75 million in Series A financing. The investors included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners LP, Boxer Capital LLC, Adage Capital Management LP and Alexandria Venture Investments.

Cyteir Therapeutics rakes in $29 mln Series B

Cambridge, Massachusetts-based Cyteir Therapeutics, a developer of synthetic lethal therapies that treat cancer and autoimmune disease, has raised $29 million in Series B financing. Venrock led the round with participation from other investors that included Celgene, Lightstone Ventures and DROIA Oncology Ventures.

Agtech funding rebounds 29 percent in 2017

Index, 5AM, Battery top maturing venture portfolio at CalPERS